Indian Pharma Market Registers 8.5% Growth In Dec 2020

Mumbai : The Indian Pharmaceutical Market (IPM) has registered a growth of 8.5 per cent for the month of December 2020, as against growth of one per cent in November 2020.

According to AIOCD AWACS report, the IPM has recorded sales of Rs. 1,45,354 crore for moving annual total (MAT) basis during December 2020.

Amongst the top 10 corporates, Cipla exhibited the highest growth of 8.9 per cent, followed by Torrent Pharma at 7.0 per cent.  Amongst the 11 to 25 ranked corporates, Glenmark Pharma exhibited highest growth of 16.3 per cent followed by Himalaya at 14.1 per cent.

Amongst the 26 to 50 ranked corporates, Apex Lab registered the highest growth of 20.1 per cent followed by Boehringer Ingelheim at 14.4 per cent. Amongst the 51 to 75 ranked corporates, Danone registered the highest growth of 33.5 per cent. Amongst the 76 to 100 ranked corporates, Reckitt Benckiser exhibited the highest growth at 23.6 per cent, followed by Llyod Hc at 14.4 per cent.

Some therapies continue the trend of revival in December 2020.Cardiac registered a monthly growth of 14.9% as compared to 8.7% in November 2020, while anti-diabetic registered growth of 9.9% in December 2020 as compared to 1.9% in November 2020.While respiratory medicines growth slumps to -8.7% in December 2020 as compared to -6.9 % in November 2020.

Post unlockdown since June 2020 the struggle for anti-infectives at 0.2% in November 2020 continues 5.2% in December 2020 and its associated therapy like gastro exhibits growth of 16.2% in December 2020 as against 3.1% in November 2020.

Vitamins have bounced back has growth of 14.0% in December 2020 as compared to 6.6 % in November 2020 and pain and analgesics are at  6.0% in December 2020 as against -5.2% in November 2020.

  • Related Posts

    4yo snakebite victim given anti-rabies shot at Sambhal hosp; pharmacist removed from duty

    Meerut: A four-year-old boy’s condition allegedly worsened after he was administered an anti-rabies injection at Sambhal district hospital following a snakebite. A pharmacist at the hospital has been removed from…

    Lupin gets tentative US FDA nod for apixaban oral suspension for patients who cannot swallow tablets

    Once final approval comes through, the liquid anticoagulant will be made at Lupin’s plant in Somerset, New Jersey, the company said. Mumbai: Lupin has received tentative approval from the US…

    Leave a Reply

    Your email address will not be published. Required fields are marked *

    You Missed

    4yo snakebite victim given anti-rabies shot at Sambhal hosp; pharmacist removed from duty

    4yo snakebite victim given anti-rabies shot at Sambhal hosp; pharmacist removed from duty

    Delhi High Court sets aside FSSAI order asking Red Bull India to drop ‘energy’ from its drinks

    Delhi High Court sets aside FSSAI order asking Red Bull India to drop ‘energy’ from its drinks

    Haryana to use Ayushman, Chirayu claim money for hospital staff incentives and upgrades: CM

    Haryana to use Ayushman, Chirayu claim money for hospital staff incentives and upgrades: CM

    Indian speciality drugs get zero duty as US widens 100% tariff on patented medicines

    Indian speciality drugs get zero duty as US widens 100% tariff on patented medicines

    Low-dose CT screening lowers lung cancer deaths by 16% in high-risk people: IARC

    Low-dose CT screening lowers lung cancer deaths by 16% in high-risk people: IARC

    Krsnaa Diagnostics board clears sale of diagnostic equipment worth up to Rs 120 crore

    Krsnaa Diagnostics board clears sale of diagnostic equipment worth up to Rs 120 crore